Last reviewed · How we verify

Apremilast 30mg

Amgen · FDA-approved active Small molecule Quality 5/100

Apremilast 30mg is a Small molecule drug developed by Amgen. It is currently FDA-approved. Also known as: CC-10004, Otezla, Apremilast tablets.

At a glance

Generic nameApremilast 30mg
Also known asCC-10004, Otezla, Apremilast tablets
SponsorAmgen
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Apremilast 30mg

What is Apremilast 30mg?

Apremilast 30mg is a Small molecule drug developed by Amgen.

Who makes Apremilast 30mg?

Apremilast 30mg is developed and marketed by Amgen (see full Amgen pipeline at /company/amgen).

Is Apremilast 30mg also known as anything else?

Apremilast 30mg is also known as CC-10004, Otezla, Apremilast tablets.

What development phase is Apremilast 30mg in?

Apremilast 30mg is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing